UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

Blood, 2014-11, Vol.124 (23), p.3345-3355

2014

Volltextzugriff (PDF)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia

Haematologica (Roma), 2022-12, Vol.107 (12), p.2776-2778

Freeman, Sylvie D

2022

Volltextzugriff (PDF)

Assessment of Minimal Residual Disease in Standard-Risk AML

The New England journal of medicine, 2016-02, Vol.374 (5), p.422-433

2016

Volltextzugriff (PDF)

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

Journal of clinical oncology, 2018-05, Vol.36 (15), p.1486-1497

2018

Volltextzugriff (PDF)

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4123-4131

2013

Volltextzugriff (PDF)

Evaluating measurable residual disease in acute myeloid leukemia

Blood advances, 2018-06, Vol.2 (11), p.1356-1366

2018

Volltextzugriff (PDF)

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia

Science translational medicine, 2013-09, Vol.5 (203), p.203ra125

2013

Volltextzugriff (PDF)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia

Cancers, 2018-06, Vol.10 (7), p.215

2018

Volltextzugriff (PDF)

Acute myeloid leukaemia

The Lancet (British edition), 2023-06, Vol.401 (10393), p.2073-2086

2023

Volltextzugriff (PDF)

Transplant in older adults with AML: genomic wheat and chaff

Blood, 2022-06, Vol.139 (24), p.3459-3461

2022

Volltextzugriff (PDF)

Reply to G. Gui et al

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2416-2417

2021

Volltextzugriff (PDF)

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia

PloS one, 2016-09, Vol.11 (9), p.e0163291-e0163291

2016

Volltextzugriff (PDF)

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

Journal of clinical oncology, 2021-03, Vol.39 (7), p.768-778

2021

Volltextzugriff (PDF)

MRD evaluation of AML in clinical practice: are we there yet?

Hematology, 2019-12, Vol.2019 (1), p.557-569

2019

Volltextzugriff (PDF)

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis

JAMA oncology, 2020-12, Vol.6 (12), p.1890

2020

Volltextzugriff (PDF)

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Hematology, 2014-12, Vol.2014 (1), p.222-233

2014

Volltextzugriff (PDF)

Siglec-5 (CD170) Can Mediate Inhibitory Signaling in the Absence of Immunoreceptor Tyrosine-based Inhibitory Motif Phosphorylation

The Journal of biological chemistry, 2005-05, Vol.280 (20), p.19843-19851

2005

Volltextzugriff (PDF)

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Blood advances, 2019-10, Vol.3 (20), p.3052-3061

2019

Volltextzugriff (PDF)

AML in the elderly—A global view

British journal of haematology, 2023-12, Vol.203 (5), p.760-773

2023

Volltextzugriff (PDF)

Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis

Leukemia, 2022-12, Vol.36 (12), p.2817-2826

2022

Volltextzugriff (PDF)

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood, 2024-05, Vol.143 (19), p.1931-1936

2024

Volltextzugriff (PDF)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Blood, 2023-11, Vol.142 (20), p.1697-1707

2023

Volltextzugriff (PDF)

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Leukemia, 2024-10, Vol.38 (10), p.2266-2269

2024

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(95)
Buchkapitel
(2)

Sprache

Englisch
(93)
Französisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(44)
Humans
(41)
Hematology
(30)
Flow Cytometry
(16)
Male
(15)
Adult
(14)
Aged
(14)
Female
(14)
Middle Aged
(14)
Leukemia, Myeloid, Acute - Drug Therapy
(13)
Leukemia, Myeloid, Acute - Genetics
(12)
Oncology
(12)
Prognosis
(12)
Leukemia
(11)
Acute Myeloid Leukemia
(10)
Leukemia, Myeloid, Acute - Diagnosis
(10)
Chemotherapy
(8)
Leukemia, Myeloid, Acute - Mortality
(8)
Leukemia, Myeloid, Acute - Therapy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

Delving the depths of measurable residual disease negativity in acute myeloid leukemia

Assessment of Minimal Residual Disease in Standard-Risk AML

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

Evaluating measurable residual disease in acute myeloid leukemia

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia

Acute myeloid leukaemia

Transplant in older adults with AML: genomic wheat and chaff

Reply to G. Gui et al

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

MRD evaluation of AML in clinical practice: are we there yet?

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Siglec-5 (CD170) Can Mediate Inhibitory Signaling in the Absence of Immunoreceptor Tyrosine-based Inhibitory Motif Phosphorylation

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

AML in the elderly—A global view

Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML

Suchergebnisse filtern